MidFirst Bank Makes New $799,000 Investment in West Pharmaceutical Services, Inc. $WST

MidFirst Bank acquired a new stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,226 shares of the medical instruments supplier’s stock, valued at approximately $799,000.

Several other institutional investors have also modified their holdings of WST. BlackRock Inc. bought a new stake in West Pharmaceutical Services in the second quarter worth $2,387,990,000. State Street Corp increased its position in West Pharmaceutical Services by 2.1% during the second quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after acquiring an additional 68,330 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in shares of West Pharmaceutical Services by 2.9% in the fourth quarter. Artisan Partners Limited Partnership now owns 2,850,401 shares of the medical instruments supplier’s stock valued at $784,259,000 after acquiring an additional 79,481 shares during the period. Bank of New York Mellon Corp purchased a new stake in shares of West Pharmaceutical Services in the second quarter valued at $733,733,000. Finally, Geode Capital Management LLC lifted its holdings in shares of West Pharmaceutical Services by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 1,869,086 shares of the medical instruments supplier’s stock worth $512,250,000 after acquiring an additional 11,962 shares during the last quarter. 93.90% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of recent analyst reports. Weiss Ratings raised shares of West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, August 7th. KeyCorp lifted their target price on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Wolfe Research started coverage on shares of West Pharmaceutical Services in a research note on Monday, June 1st. They set an “outperform” rating and a $375.00 price target for the company. Citigroup boosted their price target on West Pharmaceutical Services from $400.00 to $412.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $368.08.

West Pharmaceutical Services Stock Down 0.8%

West Pharmaceutical Services stock opened at $346.69 on Tuesday. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The firm has a market cap of $24.40 billion, a P/E ratio of 44.39, a P/E/G ratio of 2.44 and a beta of 1.15. The business has a fifty day moving average of $347.00 and a two-hundred day moving average of $296.89. West Pharmaceutical Services, Inc. has a twelve month low of $223.83 and a twelve month high of $386.00.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The business had revenue of $872.30 million for the quarter, compared to the consensus estimate of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business’s revenue was up 13.8% compared to the same quarter last year. During the same period last year, the business posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, August 5th. Shareholders of record on Wednesday, July 29th were paid a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.3%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.